CANMAB 150MG INJECTION

Content Reviewed By:

Written By:

• CANMAB 150MG INJECTION is a targeted therapy designed to combat cancer cells that exhibit an overabundance of the HER2 protein. The HER2 protein, or human epidermal growth factor receptor 2, is a receptor found on the surface of cells. In certain types of cancer, such as breast cancer and stomach cancer, HER2 is overexpressed, meaning there are too many copies of the protein on the cancer cell surface. This overexpression fuels uncontrolled cancer cell growth and proliferation.
• CANMAB 150MG INJECTION works by specifically binding to the HER2 protein on the surface of these cancer cells. This binding action has two primary effects. First, it directly inhibits the HER2 signaling pathway, effectively shutting down the signals that promote cancer cell growth. Second, it marks the cancer cells for destruction by the body's immune system. This dual mechanism of action makes CANMAB 150MG INJECTION a powerful tool in the fight against HER2-positive cancers.
• By selectively targeting HER2, CANMAB 150MG INJECTION helps to slow or stop the progression of the cancer, potentially leading to improved outcomes for patients. It's important to note that CANMAB 150MG INJECTION is typically used in combination with other chemotherapy drugs or hormone therapies as part of a comprehensive cancer treatment plan. The specific treatment regimen will depend on the individual patient's diagnosis, stage of cancer, and overall health.

• CANMAB 150MG INJECTION is administered either before or after surgery, depending on the specific treatment protocol determined by your healthcare provider. The timing of administration is carefully considered to optimize its effectiveness in your individual case.
• The initial administration of CANMAB 150MG INJECTION involves an intravenous infusion lasting approximately 90 minutes. During this period, you will be closely monitored for any adverse reactions or signs of intolerance. If the 90-minute infusion is well-tolerated, subsequent doses may be administered over a shorter duration, typically around 30 minutes. This accelerated infusion time helps to improve convenience and reduce the overall treatment time.
• It's crucial to adhere to the prescribed dosage and administration schedule provided by your doctor or nurse. Do not attempt to self-administer CANMAB 150MG INJECTION. It must be given by a trained healthcare professional in a controlled medical setting to ensure your safety and the drug's efficacy.
• Inform your healthcare provider immediately if you experience any discomfort, pain, or unusual symptoms during or after the infusion. Common side effects may include fever, chills, nausea, vomiting, headache, or dizziness. Prompt reporting of these symptoms allows for timely intervention and management.